KR20220122612A - 시롤리무스 또는 그 염을 함유하는 수성 현탁 조성물 - Google Patents

시롤리무스 또는 그 염을 함유하는 수성 현탁 조성물 Download PDF

Info

Publication number
KR20220122612A
KR20220122612A KR1020227018715A KR20227018715A KR20220122612A KR 20220122612 A KR20220122612 A KR 20220122612A KR 1020227018715 A KR1020227018715 A KR 1020227018715A KR 20227018715 A KR20227018715 A KR 20227018715A KR 20220122612 A KR20220122612 A KR 20220122612A
Authority
KR
South Korea
Prior art keywords
aqueous suspension
sirolimus
salt
suspension composition
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227018715A
Other languages
English (en)
Korean (ko)
Inventor
도요미 후지사와
아야카 아쿠타가와
Original Assignee
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산텐 세이야꾸 가부시키가이샤 filed Critical 산텐 세이야꾸 가부시키가이샤
Publication of KR20220122612A publication Critical patent/KR20220122612A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227018715A 2019-12-26 2020-12-25 시롤리무스 또는 그 염을 함유하는 수성 현탁 조성물 Ceased KR20220122612A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019237226 2019-12-26
JPJP-P-2019-237226 2019-12-26
PCT/JP2020/048738 WO2021132565A1 (ja) 2019-12-26 2020-12-25 シロリムスまたはその塩を含有する水性懸濁組成物

Publications (1)

Publication Number Publication Date
KR20220122612A true KR20220122612A (ko) 2022-09-02

Family

ID=76575568

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018715A Ceased KR20220122612A (ko) 2019-12-26 2020-12-25 시롤리무스 또는 그 염을 함유하는 수성 현탁 조성물

Country Status (9)

Country Link
US (1) US20230055121A1 (https=)
EP (1) EP4082544A4 (https=)
JP (2) JP7682103B2 (https=)
KR (1) KR20220122612A (https=)
CN (2) CN118340726A (https=)
AU (1) AU2020411442B2 (https=)
CA (1) CA3162626A1 (https=)
TW (1) TWI871406B (https=)
WO (1) WO2021132565A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116942607A (zh) * 2023-01-13 2023-10-27 杭州微致生物科技有限公司 一种西罗莫司混悬液

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194212A (ja) 1991-07-25 1993-08-03 Univ Louisville Res Found Inc 眼炎症処置方法
JP2010540682A (ja) 2007-10-08 2010-12-24 ラックス・バイオサイエンシーズ・インコーポレイテッド カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
WO2014142146A1 (ja) 2013-03-13 2014-09-18 参天製薬株式会社 マイボーム機能不全の治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
ES2507078T3 (es) * 2007-08-16 2014-10-14 Santen Pharmaceutical Co., Ltd Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
CN105833344B (zh) * 2016-04-26 2019-04-26 青岛慧生惠众生物科技有限公司 一种可注射水凝胶在制备眼内填充物中的应用
CN106420607B (zh) 2016-11-02 2019-06-28 北京诺康达医药科技股份有限公司 一种西罗莫司纳米混悬剂及其制备方法
EP3565520B1 (en) * 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
CN107334734B (zh) 2017-07-10 2020-03-17 浙江大学 一种西罗莫司或其衍生物的眼用制剂
US20200261427A1 (en) * 2019-02-20 2020-08-20 Al Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194212A (ja) 1991-07-25 1993-08-03 Univ Louisville Res Found Inc 眼炎症処置方法
JP2010540682A (ja) 2007-10-08 2010-12-24 ラックス・バイオサイエンシーズ・インコーポレイテッド カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
WO2014142146A1 (ja) 2013-03-13 2014-09-18 参天製薬株式会社 マイボーム機能不全の治療剤

Also Published As

Publication number Publication date
WO2021132565A1 (ja) 2021-07-01
TWI871406B (zh) 2025-02-01
AU2020411442B2 (en) 2026-02-12
JP7682103B2 (ja) 2025-05-23
CA3162626A1 (en) 2021-07-01
AU2020411442A1 (en) 2022-06-23
JPWO2021132565A1 (https=) 2021-07-01
US20230055121A1 (en) 2023-02-23
CN118340726A (zh) 2024-07-16
EP4082544A4 (en) 2024-01-10
JP2025111828A (ja) 2025-07-30
TW202135806A (zh) 2021-10-01
CN114845714A (zh) 2022-08-02
CN114845714B (zh) 2024-05-14
EP4082544A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
US11826429B2 (en) Pharmaceutical composition comprising brinzolamide
US8614210B2 (en) Process for preparing pharmaceutical ophthalmic compositions
EA034839B1 (ru) Офтальмологический раствор
US20180169079A1 (en) Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
US20240390515A1 (en) Multidose ophthalmic compositions
JP2025111828A (ja) シロリムスまたはその塩を含有する水性懸濁組成物
KR20160060656A (ko) 폴리에틸렌글리콜 함유 조성물
US20200206200A1 (en) Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
JP5237137B2 (ja) 眼科用剤
RU2842860C1 (ru) Водная суспензионная композиция, содержащая сиролимус или его соль
CA2866810C (en) Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
KR20230107624A (ko) 레보플록사신 및 케토롤락을 함유하는 안과용 조성물, 이의 제조 방법 및 용도
US20150119386A1 (en) Process for preparing opthalmic suspension of brinzolamide
KR20170129832A (ko) 폴리펩티드를 함유하는 의약 조성물
EA051764B1 (ru) Офтальмологическая композиция, содержащая левофлоксацин и кеторолак, способ ее получения и ее применение

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601